Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$90.17 USD

90.17
2,718,685

-0.73 (-0.80%)

Updated Jun 24, 2024 04:00 PM ET

After-Market: $90.15 -0.02 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (159 out of 249)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

CVS Health (CVS) Q1 Earnings Surpass Estimates, EPS View Cut

CVS Health's (CVS) robust sales growth across all three operating segments drives top-line results.

PacBio (PACB) Tops on Q1 Earnings, Raises FY23 Revenue View

PacBio (PACB) witnesses strong revenue growth in the first quarter. This is partly aided by customers' product transition to the Revio system.

DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Beat Estimates

DENTSPLY SIRONA's (XRAY) Q1 earnings and revenues decline year over year, driven by the unfavorable foreign currency movement and soft demand across all geographical segments.

Penumbra (PEN) Q1 Earnings Top Estimates, Sales Remain Robust

Penumbra's (PEN) sales during the first quarter reflect continued demand for its products. The 2023 outlook is encouraging as earnings improve despite macro challenges.

Inspire Medical (INSP) Q1 Earnings & Revenues Top Estimates

Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the first quarter.

Omnicell (OMCL) Q1 Earnings Top Estimates, Margins Down

Despite a year-over-year decrease, Omnicell's (OMCL) first-quarter revenues and earnings exceed the top end of the previously announced outlook amid an uncertain macroeconomic environment.

AmerisourceBergen (ABC) Beats on Q2 Earnings, Ups '23 EPS View

AmerisourceBergen's (ABC) fiscal second-quarter 2023 results benefit from segmental growth. Inflation and unfavorable currency rates hurt operating margin.

Zimmer Biomet (ZBH) Q1 Earnings Beat Estimates, View Raised

Each of Zimmer Biomet's (ZBH) geographic segments and product divisions records strong year-over-year sales growth at CER.

Hologic's (HOLX) Q2 Earnings Beat Estimates, 2023 View Up

The year-over-year growth in Breast Health and GYN Surgical Businesses contributed to Hologic's (HOLX) Q2 revenues.

IDEXX (IDXX) Q1 Earnings Beat Estimates, Margins Increase

Continued solid demand for veterinary services and record global premium instrument placements drive IDEXX's (IDXX) Q1 revenues.

Ecolab (ECL) Q1 Earnings & Revenues Beat, Margins Up

Ecolab's (ECL) robust performance across all segments drives its Q1 sales despite business challenges.

Avantor (AVTR) Q1 Earnings Surpass Estimates, Margins Down

Despite Avantor's (AVTR) strength in bioproduction and strength in Applied Technologies and Advanced Materials end markets, it reports an overall soft Q1 performance.

Stryker (SYK) Q1 Earnings Beat Estimates, Volume Improves

Stryker's (SYK) first-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs affect margins.

Merit Medical (MMSI) Tops Q1 Earnings Estimates, Ups FY23 View

Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the first quarter.

Integer Holdings (ITGR) Q1 Earnings, Revenues Beat Estimates

Integer Holdings' (ITGR) first-quarter results reflect robust Medical and Non-Medical sales, besides strength in all the product lines.

ALC or EW: Which Is the Better Value Stock Right Now?

ALC vs. EW: Which Stock Is the Better Value Option?

DexCom (DXCM) Q1 Earnings Beat Estimates, Volumes Remain Strong

DexCom's (DXCM) first-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates

ResMed (RMD) reports a solid third-quarter top line, led by strong device sales growth through steady production and delivery of its cloud-connected flow generator devices to meet high market demand.

Baxter (BAX) Beats on Q1 Earnings, Ups '23 EPS View

Baxter's (BAX) first-quarter 2023 results reflect sustained demand for its medically essential products amid a stabilizing macroeconomic climate and healthcare marketplace.

Accuray (ARAY) Q3 Earnings and Revenues Surpass Estimates

Accuray (ARAY) reports a solid fiscal third-quarter top line on the back of robust segmental performances.

Nevro (NVRO) Q1 Earnings and Revenues Surpass Estimates

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q1, partly owing to robust domestic performance.

West Pharmaceutical (WST) Q1 Earnings Beat, Order Book Strong

West Pharmaceutical's (WST) first-quarter results reflect a sustained recovery in non-COVID-19 demand amid dismal overall performance.

Surmodics (SRDX) Q2 Earnings Top Estimates, FY23 View Revised

Surmodics (SRDX) reports a solid fiscal second-quarter top line on the back of robust Medical Device revenues.

Edwards Lifesciences (EW) Q1 Earnings Top Estimates, '23 View Up

Edwards Lifesciences (EW) continues to register strong momentum in TMTT, led by the continued adoption of the PASCAL Precision system in Europe.

Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms Guidance

Strength in the VITAS and Roto-Rooter branches contributes to Chemed's (CHE) first-quarter top line.